500124

- Concall Schedule - Concall Date: Wednesday, July 22nd, 2026 - Concall Time: 19:30 PM IST / 10:00 AM ET

- Audio recording of the conference call conducted on July 9, 2026, is now available. Weblink provided for access.

- Dr. Reddy's reported that certain batches of semaglutide API were found out of specification, leading to delayed commercial supplies of the product. The company stated no impact on patient safety or existing global regulatory filings. - A conference call to discuss this issue is scheduled for Thursday, July 9, 2026, from 16:30 – 17:00 IST.

- Dr. Reddy's announced certain batches of semaglutide were out of specification due to an API issue, causing delayed commercial supplies. No impact on patient safety or global regulatory filings. A conference call to discuss this issue is scheduled for July 9, 2026, 16:30 – 17:00 IST.

- The 42nd Annual General Meeting (AGM) will be held on Thursday, July 23, 2026, at 11:00 a.m. via Video Conferencing/OAVM. - The Board recommended a final dividend of ₹8 per equity share for FY 2025-26. - The record date for the dividend is Friday, July 10, 2026, with payment on or before July 30, 2026.

- Filed Business Responsibility & Sustainability Report (BRSR) for FY2025-26. - Highlights include 80.1% employee ethical conduct training, 98% global waste diverted from landfill, and 78% electricity from renewable power. - The company reported a 50% absolute reduction in Scope 1&2 emissions from baseline year 2023 and aims to serve 1.5 billion patients by 2030.

- Notice of 42nd Annual General Meeting to be held on Thursday, July 23, 2026, at 11:00 A.M. IST via video conference. - Agenda includes adoption of financial statements for FY26, declaration of a final dividend of ₹8/- per equity share, re-appointment of directors, and appointment of Deloitte Haskins & Sells LLP as statutory auditors. - The cut-off date for e-voting is July 16, 2026, with voting from July 19-22, 2026. - Final dividend, if declared, will be paid on or before July 30, 2026.

- Consolidated Revenue ₹33,593.3 Cr vs ₹32,553.5 Cr (▲3.2% YoY) - EBITDA ₹7,659.5 Cr vs ₹9,213.3 Cr (▼16.9% YoY) - PAT ₹4,285 Cr vs ₹5,654.4 Cr (▼24.2% YoY) - EBITDA Margin 22.8% vs 28.3% (▼550bps)